{
  "meta": {
    "title": "Concepts_Of_Bleeding_Disorders",
    "url": "https://brainandscalpel.vercel.app/concepts-of-bleeding-disorders-57047c74.html",
    "scrapedAt": "2025-11-29T18:32:00.686Z"
  },
  "questions": [
    {
      "id": 15394,
      "choices": [
        {
          "id": 61536,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Extrinsic pathway </span></span></span></p>"
        },
        {
          "id": 61537,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Intrinsic pathway </span></span></span></p>"
        },
        {
          "id": 61538,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Platelet function </span></span></span></p>"
        },
        {
          "id": 61539,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Common pathway</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">A 9-year-old boy with no significant past medical history is brought to the pediatrician by his parents who are concerned about his recent onset of spontaneous bruising and a single episode of nose bleeding that took longer than expected to cease. The child has no known allergies, and there is no family history of bleeding disorders. On physical examination, the paediatrician notes several bruises of varying sizes on his legs and arms, as well as petechiae on his ankles. Initial laboratory tests reveal an elevated prothrombin time (PT) and an elevated activated partial thromboplastin time (aPTT), but a normal platelet count and bleeding time (BT). What is the most likely defect in this child&#39;s coagulation pathway?</span></span></span></span></p>",
      "unique_key": "Q3789526",
      "question_audio": null,
      "question_video": null,
      "map_id": 31747,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Ans. D) Common pathway</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"><strong>Defects </strong>in the <strong>common pathway affect factors </strong>that are involved in <strong>both the intrinsic </strong>and <strong>extrinsic pathways </strong>(such as factors X, V, II [prothrombin], and I [fibrinogen]) and would lead to <strong>elevations in both PT and aPTT</strong>, as seen in this patient.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option A. Extrinsic pathway:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> A defect in the extrinsic pathway would typically <strong>lead to an isolated elevation of PT</strong>, as this pathway is evaluated by the PT test. This does not explain the elevated aPTT observed in the patient.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option B. Intrinsic pathway:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> A defect in the intrinsic pathway would typically <strong>result in an isolated elevation of aPTT</strong>, as this pathway is evaluated by the aPTT test. This also does not explain the elevated PT observed in the patient.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option C. Platelet function:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> Platelet function defects usually result in a <strong>prolonged bleeding time </strong>(BT) and <strong>normal coagulation tests </strong>(PT and aPTT). Since the patient has a normal BT, this is unlikely to be the correct diagnosis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Educational Objective: </span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defect in the <strong>extrinsic pathway </strong>causes elevation of <strong>PT </strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defect in the <strong>intrinsic pathway </strong>causes elevation of <strong>aPTT</strong>. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Defect in <strong>common pathway </strong>cause elevation of <strong>both PT and aPTT</strong>. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet function defect </span></span></strong><span dir=\"ltr\" lang=\"EN-US\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">causes elevation of <strong>BT</strong>. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ref</span></span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">: Robbins 10<sup>th</sup>/ 120 </span></span></strong></span></span></p>",
      "correct_choice_id": 61539,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15405,
      "choices": [
        {
          "id": 61580,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">EDTA</span></span></p>"
        },
        {
          "id": 61581,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin</span></span></p>"
        },
        {
          "id": 61582,
          "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Potassium oxalate + sodium fluoride </span></span></p>"
        },
        {
          "id": 61583,
          "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tri Sodium citrate </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">As a primary healthcare worker, you collect blood samples to measure fasting blood glucose levels in a population screening for diabetes. To ensure accurate results, which anticoagulant should be used to prevent glycolysis in the sample during transport to the laboratory</span></span>? </span></span></span></p>",
      "unique_key": "Q6653533",
      "question_audio": null,
      "question_video": null,
      "map_id": 31758,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. C) Potassium oxalate + sodium fluoride</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Potassium oxalate + sodium fluoride:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> Sodium fluoride <strong>inhibits glycolysis </strong>by inhibiting the<strong> enolase enzyme in the glycolytic pathway</strong>, ensuring <strong>glucose levels remain stable</strong> after blood collection. <strong>Potassium oxalate </strong>acts as an <strong>anticoagulant. </strong>This combination is<strong> ideal for glucose estimation in blood samples.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option A. EDTA:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> <strong>Ethylenediaminetetraacetic acid </strong>(EDTA) is commonly used as an <strong>anticoagulant in hematology </strong>for<strong> complete blood</strong> <strong>count testing </strong>but not for glucose estimation because it does not prevent glycolysis.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option B. Heparin:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> Heparin is an<strong> anticoagulant </strong>that prevents blood clotting by<strong> inhibiting thrombin </strong>but does not prevent glycolysis, so it is not the best choice for glucose testing.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option D. Tri Sodium citrate:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> Trisodium citrate is used mainly for<strong> coagulation tests </strong>and <strong>does not inhibit glycolysis</strong>, making it unsuitable for glucose estimation.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Direct quote &lsquo;<strong>enolase enzyme in the glycolysis is inhibited by fluoride</strong>, and when <strong>blood samples </strong>are taken for measurement of <strong>glucose</strong>, it is<strong> collected in tubes </strong>containing<strong> fluoride to inhibit glycolysis.&rsquo;</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ref</span></span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">: Henry&rsquo;s 21<sup>st</sup> /188, Harper 27th/152 </span></span></strong></span></span></p>",
      "correct_choice_id": 61582,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14087,
      "choices": [
        {
          "id": 56309,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet functions and common pathway</span></span></span></p>"
        },
        {
          "id": 56310,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Extrinsic and common pathway</span></span></span></p>"
        },
        {
          "id": 56311,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intrinsic and common pathway</span></span></span></p>"
        },
        {
          "id": 56312,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vessel wall integrity and intrinsic pathway</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activated Partial thromboplastin time correlates with which of the following?</span></span></p>",
      "unique_key": "Q5326750",
      "question_audio": null,
      "question_video": null,
      "map_id": 31752,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Intrinsic and common pathway</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> aPTT or activated Partial thromboplastin time </strong>best correlate with<strong> intrinsic and common pathway activity</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>PT or Prothrombin time </strong>best correlate with <strong>extrinsic and common pathway activity.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> aPTT test </strong>evaluates the integrity of the <strong>intrinsic and common pathways of coagulation</strong>. It involves factors<strong> XII, XI, IX, VIII (intrinsic pathway)</strong>, and factors<strong> X, V, II (prothrombin)</strong>, and <strong>I (fibrinogen) </strong>which are part of the common pathway.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Platelet function </strong>tests assess<strong> platelet aggregation and adhesion</strong>,<strong> </strong>which are <strong>not </strong>measured by the <strong>aPTT.</strong> The <strong>aPTT test </strong>measures factors in the <strong>intrinsic and common coagulation pathways </strong>but <strong>not platelet function.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> extrinsic pathway </strong>is assessed by the <strong>Prothrombin time (PT) test </strong>and involves factor<strong> VII. </strong>The aPTT does not evaluate the extrinsic pathway.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Vessel wall integrity </strong>is <strong>not </strong>specifically assessed by the<strong> aPTT</strong>. The <strong>intrinsic pathway </strong>does involve <strong>endothelial interaction</strong>, but the aPTT test does not measure vessel wall function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> activated Partial thromboplastin time (aPTT) </strong>test evaluates the factors of the<strong> intrinsic and common coagulation pathways </strong>and is used to <strong>monitor heparin therapy, </strong>diagnose <strong>coagulation factor deficiencies</strong>, and assess the<strong> potential presence of inhibitors</strong>. </span></span></span></p>",
      "correct_choice_id": 56311,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15404,
      "choices": [
        {
          "id": 61576,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin</span></span></p>"
        },
        {
          "id": 61577,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">EDTA</span></span></p>"
        },
        {
          "id": 61578,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium oxalate </span></span></p>"
        },
        {
          "id": 61579,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3.2% trisodium citrate </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The anticoagulant of choice for anticoagulation testing:</span></span></span></p>",
      "unique_key": "Q7889064",
      "question_audio": null,
      "question_video": null,
      "map_id": 31757,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. D) 3.2% trisodium citrate </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trisodium citrate</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>calcium chelator </strong>and is commonly used as the <strong>anticoagulant of choice for coagulation </strong>testing particularly for tests like<strong> prothrombin time (PT) and activated partial thromboplastin time (APTT)</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Heparin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>anticoagulant </strong>that acts by potentiating the<strong> activity of antithrombin III, </strong>thereby <strong>inhibiting thrombin and</strong> <strong>other coagulation factors. </strong>While heparin is commonly <strong>used in clinical settings </strong>for<strong> anticoagulation,</strong> it is <strong>not the anticoagulant of choice for anticoagulation testing, </strong>as it can interfere with clotting assays.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. EDTA</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>anticoagulant </strong>that <strong>chelates calcium ions</strong>, <strong>preventing the coagulation </strong>process by <strong>inhibiting clotting factors </strong>that depend on<strong> calcium</strong>. EDTA is commonly used for<strong> collecting blood samples for hematology studies, </strong>such as<strong> complete blood counts</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sodium oxalate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> also <strong>chelates calcium ions</strong>, similar to<strong> EDTA</strong>, and is used for collecting blood samples for<strong> glucose testing (enolase acting as a glycolysis inhibitor).</strong></span></span></span></p>\r\n\r\n<p style=\"margin-left:24px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>anticoagulant of choice for anticoagulation </strong>testing is <strong>3.2% trisodium citrate.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Question Id-15404 Unique Key-Q7889064</span></strong></span></span></span></p>",
      "correct_choice_id": 61579,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15370,
      "choices": [
        {
          "id": 61440,
          "text": "<p><span style=\"font-size:12pt;\">TRALI</span></p>"
        },
        {
          "id": 61441,
          "text": "<p><span style=\"font-size:12pt;\">HLA alloimmunisation</span></p>"
        },
        {
          "id": 61442,
          "text": "<p><span style=\"font-size:12pt;\">Graft versus host disease</span></p>"
        },
        {
          "id": 61443,
          "text": "<p><span style=\"font-size:12pt;\">Immunomodulation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Irradiation of blood prior to transfusion prevents which of the following complications?</span></p>",
      "unique_key": "Q2173974",
      "question_audio": null,
      "question_video": null,
      "map_id": 31756,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. Graft versus host disease</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>(Graft versus Host Disease - GVHD):</strong> GVHD occurs when <strong>donor T cells attack the recipient's body</strong>. <strong>Irradiation of blood products deactivates these T cells</strong>, thereby <strong>preventing GVHD,</strong> which is especially important in <strong>immunocompromised recipients.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A: (TRALI - Transfusion-Related Acute Lung Injury):</strong> TRALI is a serious complication characterized by <strong>acute respiratory distress </strong>following<strong> transfusion. </strong>It is thought to be caused by <strong>donor antibodies against recipient leukocytes</strong>. Irradiation does not prevent TRALI.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B: (HLA alloimmunization):</strong> HLA alloimmunization can occur when a<strong> patient develops antibodies against HLA antigens from transfused blood</strong>. While leukoreduction can reduce the risk, irradiation of blood products does not prevent HLA alloimmunization.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D: (Immunomodulation):</strong> Immunomodulation refers to the<strong> potential immune system </strong>changes in <strong>transfusion recipients,</strong> potentially leading to an increased risk of <strong>postoperative infections </strong>and <strong>malignancy recurrence</strong>. <strong>Irradiation’s </strong>role in preventing <strong>immunomodulation </strong>is not clearly established.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Irradiation of white </strong>and <strong>red blood cells prior </strong>to transfusion is primarily used to<strong> prevent graft versus host disease.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">What happens in Transfusion associated-GVHD?</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Donor T cells attack recipient tissues.</span></li><li><span style=\"font-size:12.0pt;\">Occurs particularly in immunocompromised patients (e.g., post-transplant, chemotherapy).</span></li><li><span style=\"font-size:12.0pt;\">It is often fatal.</span></li><li><span style=\"font-size:12.0pt;\">Irradiation (typically with 25–30 Gy gamma rays) prevents T-cell proliferation.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>(Ref: Robbins 10th/e p671-2)</strong></span></p>",
      "correct_choice_id": 61442,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15427,
      "choices": [
        {
          "id": 61668,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-platelet antibodies </span></span></p>"
        },
        {
          "id": 61669,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bone marrow examination </span></span></p>"
        },
        {
          "id": 61670,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">WASP gene study </span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></p>"
        },
        {
          "id": 61671,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet function analyzer </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A young boy presented with recurrent episodes of melena. The physician also found presence of dermatitis like rashes and multiple petechiae. His platelet count was low but red cell and white blood cell counts were normal. Which of the following is the diagnostic investigation in this case?</span></span></span></p>",
      "unique_key": "Q1645499",
      "question_audio": null,
      "question_video": null,
      "map_id": 31755,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) WASP gene study</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option C:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong>WASP gene </strong>study refers to the<strong> genetic analysis of the Wiskott-Aldrich syndrome protein (WASP) gene</strong>. Wiskott-Aldrich syndrome is a <strong>rare X-linked recessive disorder </strong>characterized by <strong>thrombocytopenia, recurrent infections, and eczema</strong>. Given the clinical presentation described in the question, which includes<strong> low platelet count, dermatitis-like rashes, and petechiae, </strong>along with a<strong> young male patient</strong>, the possibility of <strong>Wiskott-Aldrich syndrome is high</strong>. Therefore, genetic analysis of the<strong> WASP gene </strong>is the appropriate <strong>diagnostic investigation </strong>in this case.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/10/picture4.jpg\" style=\"height:346px; width:1000px\" /></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option A.</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> <strong>Anti-platelet antibodies</strong> are <strong>antibodies </strong>produced by the immune system<strong> against platelets, </strong>which can result in conditions like<strong> immune thrombocytopenic purpura (ITP</strong>). While it could be considered in cases of thrombocytopenia, the clinical presentation described in the question is <strong>more indicative of a specific underlying genetic disorder</strong> rather than an autoimmune cause.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option B.</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> <strong>Bone marrow examination</strong> is a valuable diagnostic tool in cases of<strong> unexplained thrombocytopenia </strong>to assess for <strong>abnormalities in platelet production or destruction</strong>. However, in this case, the clinical presentation and history strongly suggest a <strong>specific genetic disorder </strong>rather than a primary bone marrow disorder.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option D</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">. <strong>Platelet function analyzers</strong> are used to assess<strong> platelet function </strong>in various <strong>bleeding disorders</strong>. While they may be useful in certain contexts, the clinical presentation described in the question suggests a<strong> genetic disorder </strong>rather than a <strong>primary platelet dysfunction</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Educational objective: </span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">The <strong>clinical presentation </strong>described, including<strong> thrombocytopenia, recurrent infections, and eczema</strong>, is suggestive of <strong>Wiskott-Aldrich syndrome</strong>, a <strong>rare X-linked recessive disorder</strong>. Genetic analysis of the<strong> WASP gene </strong>is the <strong>diagnostic investigation of choice </strong>to confirm the<strong> diagnosis.</strong></span></span></span></span></p>",
      "correct_choice_id": 61670,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15395,
      "choices": [
        {
          "id": 61540,
          "text": "<p><span style=\"font-size:12.0pt;\">Microangiopathic hemolytic anemia</span></p>"
        },
        {
          "id": 61541,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombocytopenia</span></p>"
        },
        {
          "id": 61542,
          "text": "<p><span style=\"font-size:12.0pt;\">Normal complement level</span></p>"
        },
        {
          "id": 61543,
          "text": "<p><span style=\"font-size:12.0pt;\">Grossly abnormal coagulation tests</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">All are true about thrombotic thrombocytopenic purpura except?</span></p>",
      "unique_key": "Q8046986",
      "question_audio": null,
      "question_video": null,
      "map_id": 31748,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. D) Grossly abnormal coagulation tests</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Thrombotic thrombocytopenic purpura </strong>(TTP) is a <strong>rare blood disorder </strong>characterized by the <strong>formation of microclots </strong>in <strong>small blood vessels throughout the body</strong>, leading to <strong>microangiopathic hemolytic anemia </strong>and <strong>thrombocytopenia</strong>. <strong>TTP </strong>is associated with a <strong>deficiency of ADAMTS13 </strong>(a disintegrin and metalloproteinase), an <strong>enzyme </strong>responsible for <strong>cleaving von Willebrand factor</strong>. TTP doesn't grossly affect the standard coagulation tests. So, the coagulation tests such as PT (prothrombin time) and APTT (activated partial thromboplastin time) are typically normal.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Microangiopathic hemolytic anemia:</strong> <strong>True</strong>. <strong>TTP </strong>is associated with the formation of <strong>microclots that damage red blood cells</strong>, leading to<strong> hemolysis.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Thrombocytopenia:</strong> <strong>True</strong>. <strong>TTP </strong>is characterized by<strong> low platelet counts </strong>due to the formation of <strong>platelet-rich microclots.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Normal complement level:</strong> <strong>True</strong>. Unlike other conditions such as <strong>hemolytic uremic syndrome (HUS), TTP is not </strong>typically associated with<strong> complement activation, </strong>so complement levels are generally<strong> normal</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>TTP doesn't </strong>grossly <strong>affect the standard coagulation tests</strong>. So, the <strong>coagulation tests </strong>such as <strong>PT </strong>(prothrombin time) and <strong>APTT </strong>(activated partial thromboplastin time) are typically <strong>normal</strong>. Direct lines from Robbins… “If<strong> coagulation tests </strong>indicate a <strong>major consumption of procoagulants, </strong>the diagnosis of <strong>TTP is doubtful</strong>”.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\">Mnemonic for TTP Clinical Features (Pentad):</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">FAT RN</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Fever</span></li><li><span style=\"font-size:12.0pt;\">Anemia (microangiopathic hemolytic)</span></li><li><span style=\"font-size:12.0pt;\">Thrombocytopenia</span></li><li><span style=\"font-size:12.0pt;\">Renal dysfunction (mild to moderate)</span></li><li><span style=\"font-size:12.0pt;\">Neurologic symptoms</span></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Robbins 10<sup>th</sup>/ 665</strong></span></p>",
      "correct_choice_id": 61543,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15397,
      "choices": [
        {
          "id": 61548,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic thrombocytopenia purpura (ITP)</span></span></p>"
        },
        {
          "id": 61549,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bernard Soulier syndrome </span></span></p>"
        },
        {
          "id": 61550,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Disseminated intravascular coagulation </span></span></p>"
        },
        {
          "id": 61551,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wiskott Aldrich syndrome </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">A 4-year-old boy is brought to the clinic with a history of recurrent ear infections, easy bruising, and severe eczema. On examination, the child has widespread petechiae and a weeping rash over his arms and legs. Laboratory tests reveal thrombocytopenia with an average platelet volume less than the reference range. The boy&#39;s immunoglobulin levels are also noted to be abnormally low. </span>The presence of small sized platelets on the peripheral smear is characteristic of:</span></span></span></p>",
      "unique_key": "Q2872580",
      "question_audio": null,
      "question_video": null,
      "map_id": 31750,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. D) Wiskott Aldrich syndrome </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option D: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Wiskott Aldrich syndrome </span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">is characterized by the <strong>triad </strong>of: </span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe eczema </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombocytopenia </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recurrent infections </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"><strong>Wiskott-Aldrich syndrome </strong>is characterized by the<strong> triad of eczema, thrombocytopenia (with small platelets), and immunodeficiency, </strong>which corresponds to the clinical presentation of this patient.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option A. Idiopathic thrombocytopenic purpura [ITP]:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> ITP is characterized by <strong>autoimmune destruction of platelets</strong>, typically leading to<strong> thrombocytopenia with normal-sized platelets </strong>and no associated eczema or immunodeficiency.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option B. Bernard-Soulier syndrome:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> Bernard-Soulier syndrome is a <strong>platelet function disorder </strong>due to a deficiency in<strong> glycoprotein Ib,</strong> the platelet receptor for <strong>von Willebrand factor</strong>. Patients may have <strong>thrombocytopenia </strong>with large platelets and no associated eczema or immunodeficiency.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option C. Disseminated intravascular coagulation [DIC]:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> DIC is a secondary condition resulting from another <strong>underlying disease</strong>. It is characterized by widespread <strong>activation of coagulation</strong>, which can lead to the <strong>consumption of platelets and coagulation factors</strong>. Platelet size is typically not affected, and it is not associated with eczema or immunodeficiency.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">The characteristic features of <strong>Wiskott-Aldrich syndrome</strong>, include<strong> thrombocytopenia with small platelets, eczema, and recurrent infections </strong>due to immunodeficiency. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ref</span></span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">: Robbins 10<sup>th</sup>/ 243 </span></span></strong></span></span></p>",
      "correct_choice_id": 61551,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15393,
      "choices": [
        {
          "id": 61532,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal platelet count and normal bleeding time </span></span></p>"
        },
        {
          "id": 61533,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal platelet count and increased bleeding time </span></span></p>"
        },
        {
          "id": 61534,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased platelet count and increased bleeding time</span></span></p>"
        },
        {
          "id": 61535,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal platelet count and decreased bleeding time</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patient with bleeding due to platelet function defects has which of the following features?</span></span></span></p>",
      "unique_key": "Q2549306",
      "question_audio": null,
      "question_video": null,
      "map_id": 31746,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. B) Normal platelet count and increased </span></span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">bleeding time </span></span></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This option is characteristic of <strong>platelet function defects. </strong>Although there is a <strong>normal quantity of platelets </strong>(platelet count), the <strong>quality or function of these platelets is compromised</strong>, which means they don&#39;t work as they should, leading to a prolonged bleeding time</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Platelet function defects </strong>typically result in <strong>impaired platelet aggregation or adhesion</strong>, leading to <strong>increased bleeding time</strong>. However, the <strong>platelet count remains normal </strong>in these conditions because the <strong>number of platelets is adequate</strong>, but their function is compromised. Therefore, the features of bleeding due to platelet function defects include a normal platelet count and an increased bleeding time.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Normal platelet count and normal bleeding time:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This option would suggest <strong>no defect in platelet function </strong>or <strong>number</strong>, which would not typically be associated with a bleeding disorder.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Decreased platelet count and increased bleeding time:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This suggests a <strong>quantitative defect of platelets</strong>, such as <strong>thrombocytopenia</strong>, rather than a functional defect. Although patients with thrombocytopenia will also have an increased bleeding time, the platelet count in functional defects remains normal.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Normal platelet count and decreased bleeding time:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>decreased bleeding time </strong>indicates an <strong>efficient clotting process</strong>, which would not align with platelet function defects.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Platelet function defects </strong>present with a <strong>normal platelet count </strong>but <strong>impaired function</strong>, leading to an <strong>increased bleeding time</strong>, whereas <strong>quantitative disorders </strong>would show an <strong>altered platelet count</strong>. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ref</span></span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">: Robbins 10<sup>th</sup>/ 655</span></span></strong></span></span></p>",
      "correct_choice_id": 61533,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15418,
      "choices": [
        {
          "id": 61632,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prolonged PTT </span></span></p>"
        },
        {
          "id": 61633,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prolonged PT </span></span></p>"
        },
        {
          "id": 61634,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low platelet count </span></span></p>"
        },
        {
          "id": 61635,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abnormal BT </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">A 23-year-old male presents to the clinic with recurrent, spontaneous joint hemarthroses. Family history is significant for similar symptoms in his maternal uncles. Laboratory evaluation reveals a specific factor deficiency. Which laboratory finding is most consistent with a diagnosis of Hemophilia A? </span></span></span></span></span></p>",
      "unique_key": "Q7080398",
      "question_audio": null,
      "question_video": null,
      "map_id": 31759,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Prolonged PTT </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTT </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">is prolonged by <strong>deficiency </strong>of factors <strong>XII, XI, IX, III, X, V, prothrombin and fibrinogen</strong></span> <span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">and drugs like <strong>hep&shy;arin </strong></span>&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemophilia A </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">is characterized by the deficiency of <strong>factor 8 </strong>and decreased activity of intrinsic pathway. This is associated with prolongation of <strong>partial thromboplastin time</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Prolonged PTT:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> This is the correct answer. <strong>Hemophilia A </strong>is caused by a <strong>deficiency in factor VIII</strong>, which is part of the <strong>intrinsic coagulation pathway</strong>. The <strong>activated partial thromboplastin time (PTT) test </strong>evaluates the <strong>intrinsic and common coagulation pathways </strong>and will be <strong>prolonged in Hemophilia A.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option B. Prolonged PT:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> The prothrombin time (PT) test evaluates the <strong>extrinsic and common pathways</strong>. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option C. Low platelet count:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Hemophilia A <strong>does not </strong>affect the <strong>platelet count</strong>; it is a <strong>coagulation factor deficiency </strong>and does not involve <strong>quantitative platelet defects.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option D. Abnormal BT</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">: Bleeding time tests <strong>primary hemostasis</strong>, which includes <strong>platelet function</strong>. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Educational Objective: </span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><strong>Hemophilia A</strong>, a genetic disorder characterized by <strong>factor VIII deficiency </strong>leads to<strong> impaired </strong>function of the<strong> intrinsic coagulation pathway</strong>. This manifests clinically with a<strong> prolonged activated partial thromboplastin time (PTT) and a normal prothrombin time (PT) and bleeding time (BT).</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 668</span></strong></span></span></p>",
      "correct_choice_id": 61632,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15398,
      "choices": [
        {
          "id": 61552,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Defect platelet function</span></p>"
        },
        {
          "id": 61553,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Reduced factor VIII in plasma</span></p>"
        },
        {
          "id": 61554,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Defective platelet adhesion</span></p>"
        },
        {
          "id": 61555,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"color:black;font-size:12pt;\">A 28-year-old female presents with easy bruising and prolonged bleeding after minor injuries. She has a family history of bleeding disorders. Which of the following is caused by VWF factor deficiency?</span></p>",
      "unique_key": "Q9710633",
      "question_audio": null,
      "question_video": null,
      "map_id": 31751,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"color:black;font-size:12pt;\"><strong>Ans. D) All of the above</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"color:black;font-size:12pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Von Willebrand factor (VWF) deficiency </strong>can lead to several effects on the <strong>coagulation process:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Defect platelet function:</strong> <strong>True</strong>. VWF plays a crucial role in <strong>platelet adhesion by binding to platelets </strong>and stabilizing the interaction between <strong>platelets and the damaged blood vessel wall</strong>. Its <strong>reduced levels lead to reduced platelet functioning</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Reduced factor VIII in plasma:</strong> <strong>True</strong>. VWF serves as a <strong>carrier protein for factor VIII</strong>, protecting it from rapid <strong>clearance and degradation</strong>. Therefore, a deficiency in VWF can result in <strong>decreased levels of factor VIII </strong>in the plasma.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Defective platelet adhesion</strong>:<strong> True</strong>. VWF is essential for the initial <strong>adhesion of platelets to the damaged blood vessel wall</strong>, facilitating the formation of a <strong>stable plug at the site of injury.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">So, the correct answer is (d) All of the above. <strong>Von Willebrand factor deficiency </strong>affects both<strong> platelet function and factor VIII levels in the plasma</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"background-color:white;color:#0d0d0d;font-size:12pt;\">VWF deficiency impairs <strong>platelet adhesion and aggregation </strong>at the site of <strong>vascular injury, </strong>and <strong>reduces the plasma level of factor VIII </strong>by<strong> decreasing its stability </strong>in circulation.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"color:black;font-size:12pt;\"><strong><u>Ref</u>: Robbins 10<sup>th</sup>/ 660</strong></span></p>",
      "correct_choice_id": 61555,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15396,
      "choices": [
        {
          "id": 61544,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Idiopathic thrombocytopenia purpura </span></span></p>"
        },
        {
          "id": 61545,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Systemic lupus erythematosus </span></span></p>"
        },
        {
          "id": 61546,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aplastic anemia </span></span></p>"
        },
        {
          "id": 61547,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Disseminated intravascular coagulation (DIC) </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span style=\"background-color:white\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">A 50-year-old male presents with fatigue and widespread purpura. Blood work reveals a marked decrease in platelets, with counts persistently below 20,000/&micro;L. The patient&#39;s history includes recurrent epistaxis and one instance of hematuria. Bone marrow biopsy reveals a hypocellular marrow with a markedly reduced number of megakaryocytes. </span></span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following can cause megakaryocytic thrombocytopenia, except: </span></span></span></span></p>",
      "unique_key": "Q9054851",
      "question_audio": null,
      "question_video": null,
      "map_id": 31749,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. C) Aplastic anemia </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aplastic anemia </strong>involves the <strong>failure of bone marrow production </strong>leading to <strong>pancytopenia</strong>, including a <strong>severe reduction in megakaryocytes</strong>. This condition is characterized by a <strong>low number of all cell lines </strong>(including megakaryocytes) and is <strong>not associated with megakaryocytic thrombocytopenia </strong>but rather with hypoplastic or amegakaryocytic thrombocytopenia</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option A. Idiopathic thrombocytopenic purpura [ITP]:&nbsp;</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">ITP is characterized by <strong>autoimmune destruction of platelets</strong>. It typically presents with isolated thrombocytopenia and may show an increased number of megakaryocytes in the bone marrow due to compensatory production.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option B. Systemic lupus erythematosus [SLE]:&nbsp;</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">SLE can <strong>cause thrombocytopenia </strong>due to <strong>autoantibody-mediated platelet destruction</strong>. Megakaryocytes may be increased in the bone marrow as the body tries to compensate for the peripheral platelet destruction.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option D. Disseminated intravascular coagulation [DIC]:&nbsp;</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">DIC is a condition that <strong>leads to the systemic activation of the coagulation cascade</strong>, resulting in <strong>widespread microthrombi </strong>and <strong>secondary consumption of platelets </strong>and <strong>coagulation factors</strong>. This can also lead to a compensatory increase in megakaryocytes in the bone marrow.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">In <strong>megakaryocytic thrombocytopenia</strong>, there is an <strong>increase in bone marrow megakaryocytes </strong>as a <strong>compensatory mechanism </strong>for <strong>peripheral platelet destruction</strong>, but in aplastic anemia, there is bone marrow failure and reduced megakaryocytes. </span></span></span></span></p>",
      "correct_choice_id": 61546,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15392,
      "choices": [
        {
          "id": 61528,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate refrigeration to preserve factor viability </span></span></p>"
        },
        {
          "id": 61529,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet-rich plasma is essential </span></span></p>"
        },
        {
          "id": 61530,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Done within 2 hours </span></span></p>"
        },
        {
          "id": 61531,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activated with kaolin </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">True about prothrombin time to:</span></span></span></p>",
      "unique_key": "Q8254468",
      "question_audio": null,
      "question_video": null,
      "map_id": 31745,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Done within 2 hours </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Done within 2 hours:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> <strong>PT testing </strong>should be performed within a <strong>specified time from sample collection</strong>, often <strong>within 2 hours</strong>, to ensure the <strong>viability of the coagulation factors</strong>, especially the <strong>labile factors V and VIII, </strong>which can deteriorate over time at room temperature.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option A. Immediate refrigeration to preserve factor viability:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> While it&#39;s true that certain <strong>coagulation factors </strong>are <strong>temperature sensitive</strong>, <strong>prothrombin time </strong>(PT) <strong>testing </strong>typically requires the sample to be <strong>kept at room temperature </strong>to <strong>prevent the cold activation of factors </strong>and potential precipitation of fibrinogen. Immediate refrigeration is not required for PT.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option B. Platelet-rich plasma is essential:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> <strong>PT </strong>is actually <strong>performed </strong>on <strong>platelet-poor plasma</strong>, not platelet-rich plasma. The presence of platelets can affect the test results by providing phospholipid surfaces that could artificially shorten the clotting time.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Option D. Activated with kaolin:</span></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"> <strong>PT </strong>is <strong>not activated with kaolin</strong>. Instead, <strong>thromboplastin </strong>(a combination of tissue factor and phospholipids) is used to <strong>activate the extrinsic pathway of coagulation</strong>. Kaolin is used as an activator in the activated partial thromboplastin time (aPTT) test, which evaluates the intrinsic pathway.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">Educational Objective:</span></span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\">The <strong>PT test </strong>must be <strong>done on platelet-poor plasma </strong>and usually <strong>within 2 hours of sample collection </strong>to ensure <strong>accurate results</strong>, using <strong>thromboplastin for activation. </strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#0d0d0d\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/10/picture1_R5zNr7B.jpg\" style=\"height:270px; width:500px\" /></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Dacie and Lewis practical hematology 10th/392, 398</span></strong></span></span></span></p>",
      "correct_choice_id": 61530,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15400,
      "choices": [
        {
          "id": 61560,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most of the patients respond to immunosuppressive doses of glucocorticoids</span></span></p>"
        },
        {
          "id": 61561,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Relapse is rare </span></span></p>"
        },
        {
          "id": 61562,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Splenectomy is the treatment of choice for relapse </span></span></p>"
        },
        {
          "id": 61563,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Minority have refractory forms of ITP and difficult to treat </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"background-color:white\"><span style=\"color:#0d0d0d\">A 32-year-old woman with a diagnosis of chronic immune thrombocytopenic purpura (ITP) returns for a follow-up visit. She previously responded well to a course of glucocorticoids but presented again with petechiae and a platelet count of 25,000/&mu;L. She has no splenomegaly on examination. </span></span>All the following statements are correct about treatment in chronic immune thrombocytopenic purpura except:</span></span></span></p>",
      "unique_key": "Q4434540",
      "question_audio": null,
      "question_video": null,
      "map_id": 31754,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. B) Relapse is rare </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>incorrect </strong>because <strong>relapses after initial treatment with glucocorticoids </strong>are common in<strong> chronic ITP.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. While initial treatment with<strong> glucocorticoids </strong>can be effective, many patients with <strong>chronic ITP </strong>may <strong>not </strong>achieve sustained <strong>remission and can experience relapses.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Splenectomy </strong>is typically considered <strong>after glucocorticoids and other medical therapies have failed</strong>, making it not a first-line treatment, but rather a treatment for <strong>relapsed or refractory cases</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Some patients with<strong> chronic ITP </strong>do not respond to <strong>conventional therapies or relapse following initial therapy</strong>, which may suggest a<strong> refractory form of the disease</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Direct quote&hellip;. &ldquo;Almost all patients<strong> respond to gluco&shy;corticoids </strong>(which inhibit phagocyte function), but<strong> many eventually relapse</strong>.&rdquo; </span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In individuals with <strong>severe thrombocytopenia, sple&shy;nectomy normalizes</strong> the <strong>platelet counts. </strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Immunomodulatory agents</strong> such as <strong>intravenous immunoglobulin or anti-CD20 antibody (rituximab) </strong>are often effective in patients who <strong>relapse after splenectomy </strong>or for whom <strong>splenectomy is contraindicated. </strong></span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 659</span></strong></span></span></span></p>",
      "correct_choice_id": 61561,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15399,
      "choices": [
        {
          "id": 61556,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bernard Soulier syndrome </span></span></p>"
        },
        {
          "id": 61557,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glanzmann disease </span></span></p>"
        },
        {
          "id": 61558,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Von willebrand disease </span></span></p>"
        },
        {
          "id": 61559,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gray platelet syndrome </span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 22-year-old male presents with a history of recurrent nosebleeds, easy bruising, and prolonged bleeding after minor injuries. He has a deficiency of glycoprotein IIb-IIIa complex. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glycoprotein IIb-IIIa complex is deficient in which of the following conditions? </span></span></span></p>",
      "unique_key": "Q2348333",
      "question_audio": null,
      "question_video": null,
      "map_id": 31753,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. B) Glanzmann disease </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Glanzmann disease </strong>is a <strong>congenital platelet disorder </strong>characterized by a deficiency or dysfunction of the <strong>glycoprotein IIb-IIIa complex </strong>on the surface of platelets. This complex is essential for <strong>platelet aggregation by binding fibrinogen </strong>and facilitating <strong>platelet-platelet interaction</strong>. In Glanzmann disease, i<strong>mpaired platelet aggregation </strong>leads to a tendency for <strong>prolonged bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Bernard Soulier syndrome</strong> is associated with a deficiency of<strong> glycoprotein Ib-IX-V complex</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>von Willebrand disease</strong> is associated with deficiencies or dysfunction of <strong>von Willebrand factor</strong>, not the glycoprotein IIb-IIIa complex.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Gray platelet syndrome</strong> is a <strong>rare platelet disorder </strong>characterized by <strong>grayish platelets and a deficiency of alpha-granules.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong>&nbsp;</strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Glycoprotein IIb-IIIa complex </strong>is deficient in <strong>Glanzmann&rsquo;s disease</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Book Antiqua&quot;,serif\"><span style=\"color:black\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> /120</span></strong></span></span></span></p>",
      "correct_choice_id": 61557,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15389,
      "choices": [
        {
          "id": 61516,
          "text": "<p><span style=\"font-size:12.0pt;\">Factor X deficiency</span></p>"
        },
        {
          "id": 61517,
          "text": "<p><span style=\"font-size:12.0pt;\">Glanzmann’s thrombasthenia</span></p>"
        },
        {
          "id": 61518,
          "text": "<p><span style=\"font-size:12.0pt;\">Von Willebrand disease&nbsp;</span></p>"
        },
        {
          "id": 61519,
          "text": "<p><span style=\"font-size:12.0pt;\">Bernard Soulier disease</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"color:black;font-size:12pt;\">A newborn baby presented with profuse bleeding from the umbilical stump after birth. Rest of the examination and PT, APTT are within normal limits. Most likely diagnosis is which of the following?</span></p>",
      "unique_key": "Q8220259",
      "question_audio": null,
      "question_video": null,
      "map_id": 31760,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B) Glanzmann’s thrombasthenia &gt; (d) Bernard Soulier disease</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Glanzmann’s thrombasthenia </strong>is a <strong>rare genetic platelet disorder </strong>characterized by the <strong>lack of glycoprotein IIb/IIIa </strong>on the <strong>platelet surface</strong>, which is essential for <strong>platelet aggregation</strong>. Despite normal PT and aPTT, patients present with bleeding symptoms because the coagulation cascade is intact, but the platelet plug formation is impaired.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Factor X deficiency:</strong> Factor X deficiency is a <strong>rare bleeding disorder </strong>where the <strong>clotting factor X </strong>is either <strong>deficient or not functioning properly</strong>. It typically presents with a <strong>prolonged prothrombin time </strong>(PT) and <strong>activated partial thromboplastin time </strong>(aPTT), which are not normal in this case.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. von Willebrand disease:</strong> Von Willebrand disease is the <strong>most common hereditary bleeding disorder </strong>and is caused by a <strong>qualitative or quantitative deficiency of von Willebrand factor </strong>(vWF). vWF is crucial for platelet adhesion; however, PT and aPTT can be normal in mild cases, but there's often an abnormal bleeding time or abnormal vWF assays.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Bernard-Soulier disease:</strong> Bernard-Soulier syndrome is another <strong>rare platelet disorder</strong>, caused by a <strong>deficiency or dysfunction of the platelet glycoprotein Ib-IX-V complex</strong>, important for platelet adhesion to the vascular subendothelium. Similar to Glanzmann’s thrombasthenia, PT and aPTT are normal, but the platelet function is impaired, leading to bleeding.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objective</u></strong><u>:</u></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>presence of normal PT </strong>and <strong>aPTT despite bleeding symptoms </strong>points towards a <strong>platelet function disorder </strong>rather than a <strong>clotting factor deficiency</strong>. <strong>Glanzmann’s thrombasthenia </strong>and <strong>Bernard-Soulier syndrome </strong>are both characterized by <strong>normal coagulation tests </strong>and <strong>abnormal platelet function</strong>; however, Glanzmann’s thrombasthenia is generally considered more likely when these two conditions are indistinguishable based on clinical and laboratory findings.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\">Factor XIII Deficiency and Umbilical Stump Bleeding</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Key Features of Factor XIII Deficiency:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Autosomal recessive</span></li><li><span style=\"font-size:12.0pt;\">Rare, but classically causes delayed bleeding (e.g., 24–48 hours or later)</span></li><li><span style=\"font-size:12.0pt;\">Umbilical stump bleeding is one of the hallmark early signs</span></li><li><span style=\"font-size:12.0pt;\">Clot is formed but is unstable — leading to rebleeding</span></li><li><span style=\"font-size:12.0pt;\">PT, APTT, bleeding time, and platelet count are all normal</span></li><li><span style=\"font-size:12.0pt;\">Diagnosed by 5M urea clot solubility test or Factor XIII assay</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">But it’s not in the option so the best option here is Glanzmann’s thrombasthenia</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Wintrobe’s 12th/1365-1370</strong></span></p>",
      "correct_choice_id": 61517,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15391,
      "choices": [
        {
          "id": 61524,
          "text": "<p><span style=\"font-size:12.0pt;\">Factor IX deficiency</span></p>"
        },
        {
          "id": 61525,
          "text": "<p><span style=\"font-size:12.0pt;\">Lupus anticoagulant</span></p>"
        },
        {
          "id": 61526,
          "text": "<p><span style=\"font-size:12.0pt;\">Factor VIII inhibitors</span></p>"
        },
        {
          "id": 61527,
          "text": "<p><span style=\"font-size:12.0pt;\">VWD – Type III</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 25 years old asymptomatic pregnant female underwent a pre-op coagulation test. Her bleeding time is 3 minutes, PT is 15/14sec, a PTT is 45/35 sec, platelet count is 2.5 lac/ mm</span><span style=\"color:black;font-size:5.0pt;\"><strong><sup>3</sup></strong></span><span style=\"font-size:12pt;\"> and factor VIII levels were 60IU/dL. What is her most likely diagnosis?</span></p>",
      "unique_key": "Q2512026",
      "question_audio": null,
      "question_video": null,
      "map_id": 31761,
      "difficulty_level": "difficult",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Ans. C) Factor VIII inhibitors</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option C:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Acquired hemophilia</strong>, caused by <strong>autoantibodies against factor VIII</strong>, leads to a <strong>prolonged aPTT </strong>in the <strong>presence of a normal PT </strong>and <strong>bleeding time</strong>, which matches our patient’s coagulation profile. It can occur in the absence of an underlying condition or be associated with conditions like pregnancy, as mentioned.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:16px;\">(3 minutes is the normal bleeding time)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option A. Factor IX deficiency:</strong> Factor IX deficiency, also known as <strong>Hemophilia B </strong>or <strong>Christmas disease</strong>, is a <strong>bleeding disorder </strong>caused by a <strong>deficiency of clotting factor IX</strong>. It is an <strong>X-linked recessive disorder</strong>, making it much <strong>less likely in females</strong>. It presents with a <strong>prolonged aPTT </strong>but <strong>normal PT </strong>and <strong>bleeding time</strong>, which does not fully match the patient's profile since her PT and bleeding time are within normal limits.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option B. Lupus anticoagulant:</strong> The presence of lupus anticoagulant, an <strong>autoimmune inhibitor</strong>, is associated with <strong>prolonged aPTT </strong>and may also <strong>lead to a prolonged PT</strong>. It is part of the antiphospholipid syndrome and can cause both bleeding and thrombotic episodes. Patients often have thrombocytopenia, which is not the case here as the patient has a normal platelet count.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong>Option D. VWD – Type III:</strong> Von Willebrand Disease (VWD) Type III is the <strong>most severe form of VWD </strong>and is characterized by a <strong>markedly reduced </strong>or <strong>absent von Willebrand factor</strong>, leading to a significant <strong>bleeding tendency</strong>. Patients usually have a prolonged bleeding time and a decreased factor VIII activity, which is not consistent with this patient's normal bleeding time and near-normal factor VIII levels.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\">This patient’s <strong>normal bleeding time </strong>and <strong>PT but prolonged aPTT, </strong>along with the <strong>presence of normal factor VIII activity</strong>, suggest the <strong>presence of an inhibitor against factor VIII </strong>rather than a deficiency, which is consistent with <strong>acquired hemophilia</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><strong><u>Ref</u>: Robbins 10<sup>th</sup> 672-3, Wintrobe 12th/1447-1453, Har­rison 21<sup>st</sup>/980</strong></span></p>",
      "correct_choice_id": 61526,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}